PATENT APPLICATION DOCKET NO.: 2478.2018-001

JUL 1 2 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

John M. Williams

Application No.:

10/719,055

Group Art Unit: 3739

Filed:

November 21, 2003

Examiner:

Not yet assigned

Confirmation No.:

9135

Title:

Inhibition of Chronic Tissue Transplant Rejection

CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, or is being facsimile transmitted to the United States Patent and Trademark Office on: ∕Date Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:	
This [Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or [] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper. (Filed after payment of issue fee)

Statem	ient Und	der 3/(CFR 1.97(e)		
[]	any co	mmuni	information contained in this Information Disclosure Statement was first cited in cation from a foreign patent office in a counterpart foreign application not more nths prior to the filing of this Information Disclosure Statement; or		
[]	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
<u>Staten</u>	nent Un	der 37 (CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000		
[]	comm was no	unication traceive	information contained in the Information Disclosure Statement was cited in a on from a foreign patent office in a counterpart application and this communication wed by any individual designated in § 1.56(c) more than thirty days prior to the aformation Disclosure Statement.		
[X]	Enclos	sed here	ewith is form PTO-1449:		
	[X]	Copie	s of the cited references are enclosed.		
		[X]	Since this application was filed after June 30, 2003, copies of issued U.S. patents and published U.S. applications are not required and are not being provided.		
	[]	Applie	s of the cited references are enclosed except those entered in prior application, U.S. cation No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier ation contains copies of the cited references.]		
	[X]	The li Searcl	sted references, AL, AM, AN, AS and AT, were cited in the enclosed International Reports in counterpart foreign applications.		
	[]	The "o	concise explanation" requirement (non-English references) for reference(s) [37 CFR 1.98(a)(3) is satisfied by:		
		[]	the explanation provided on the attached sheet.		
		[]	the explanation provided in the Specification.		
		[]	submission of the enclosed International Search Report.		
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.		
		[]	the enclosed English language abstract.		

[X]	Applic	cant requests that the following non-	published pending applic	ations be considered:
Examiner's Initials				
		U.S. Patent Application No. 10/719 Docket No.: 2478.2017-001	9,701, by John M. Willia	ms, filed November 21, 2003,
		U.S. Patent Application No. [],	by [inventor(s)], filed [], Docket No.: []
		U.S. Patent Application No. [],	by [inventor(s)], filed [], Docket No.: []
		Examiner	Date	-
	[X]	A copy of each above-cited applica	ation, including the curre	nt claims, is enclosed.
	[]	A copy of each above-cited application, 35 U.S.C. 120 is claimed.	ation, including the current U.S. Application No. [nt claims, is enclosed, except], to which priority under
The E	xamine nces we	er is requested to return a copy of the ere considered with the next office co	above list of pending appommunication.	olications indicating which
It is re	quested	d that the information disclosed here	in be made of record in the	nis application.
Metho	od of pa	ayment:		
[]	A che	eck for the fee noted above is enclose npanying Reply. A copy of this State	ed, or the fee has been incement is enclosed.	luded in the check with the
[]	Please	e charge Deposit Account 08-0380 in sed.	n the amount of \$[]	. A copy of this Statement is
[X]	Please	e charge any deficiency in fees and c	redit any overpayment to	Deposit Account 08-0380.
		Resp	pectfully submitted,	
		НАМ	MILTON, BROOK, SMI	TH & REYNOLDS, P.C.
		By Kr Kr Re Te Fa	raig K. (Anderson egistration No.: 54,961 elephone: (978) 341-0036 acsimile: (978) 341-0136	

Concord, MA 01742-9133 Dated: July 8, 2004

PTO-1449 REPRODUCED	•		APPLICATION NO. 10/719,055		
O 'INFORMATION DISCLOSURE CITATION ON AN APPLICATION JUL 1 2 2004	· · · · · · · · · · · · · · · · · · ·		FILING DATE November	FILING DATE November 21, 2003	
July 2, 2004 July 2, 2004 RADE TRADE	EXAMINER Not yet assigned	CONF 9135	IRMATION NO.	GROUP 3739	

	U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT			
	АА	5,540,931	07-30-1996	Hewitt, et al.			
	AB	5,654,312	08-05-1997	Andrulis, Jr., et al.			
	AC	5,795,967	08-18-1998	Aggarwal, et al.			
	AD	5,801,193	09-01-1998	Ojo-Amaize, et al.			
÷	AE	5,958,413	09-28-1999	Anagnostopulos, et al.			
	AF	5,990,103	11-23-1999	Schonharting, et al.			
•	AG	6,020,323	02-01-2000	Cohen, et al.			
	АН	6,030,615	02-29-2000	Bucala, et al.			
	AI	6,204,245	03-20-2001	Siegel, et al.			
	AJ	6,211,160	04-03-2001	Wilson, et al.			
	AK	6,235,281	05-22-2001	Stenzel, et al.			
	AA2	6,294,170	09-25-2001	Boone, et al.			
	AB2	6,270,766 B1	08-07-2001	Feldman, et al.			
	AC2	6,299,878	10-09-2001	Pierpadi, et al.			
	AD2	6,306,820 B1	10-23-2001	Bendele, et al.			
	AE2	6,331,560	12-18-2001	Shohami, et al.			
	AF2	6,337,325	01-08-2002	Schonharting, et al.			
	AG2	6,376,665	04-23-2002	Duan, et al.			
	AH2	6,420,374 B1	07-16-2002	Bianco, et al.			
	AI2	6,432,962	08-13-2002	Horneman			
	AJ2	6,432,968 B1	08-13-2002	Schonharting, et al.			
	AK2	6,503,184	01-07-2003	Ni, et al.			
	AA3	6,506,569 B1	01-14-2003	Ni, et al.			
	AB3	6,509,015 B1	01-21-2003	Salfeld, et al.			
	AC3	2002/0119988 A1	08-29-2002	Sneddon, et al.			

EXAMINER	DATE CONSIDERED
	3.1.2 00.10158.25
i	

PTO-1449 REPRODUCED			tication no. 719,055		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	FIRST NAMED INVENTOR John M. Williams FILING DATE November 2		21, 2003		
July 2, 2004 (Use several sheets if necessary)	EXAMINER Not yet assigned	CONFI 9135	RMATION NO.	GROUP 3739	

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSL/ YES	ATION NO	
AL	WO 01/87849	11-22-2001	Genzyme Corporation			
AM	WO 98/39026	09-11-1998	Biogen Inc.			
AN	EP 0 401 747 A	12-12-1990	Calne		·	
AO	WO 95/09652	04-13-1995	The Kennedy Institute for Rheumatology			
AP	WO 94/08619	04-28-1994	The Kennedy Institute for Rheumatology			

 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
AR	Yuan, X. et al., "A novel CD154 monoclonal antibody in acute and chronic rat vascularized cardiac allograft rejection," <i>Transplantation</i> 73(11):1736-1742 (2002).				
AS	Turner, D. M., et al., "A Genetic Marker of High TNF-α Production in Heart Transplant Recipients," Transplantation, 60(10):1113-1117 (1995).				
AT	Couriel, D., et al., "TNF-Alpha Inhibition for the Treatment of Chronic GVHD," Blood, 100(11):847a (2002) Abstract.				
AU	Hancock, W. W., et al., "Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection," <i>Proc. Natl. Acad. Sci. USA 93</i> :13967-13972 (1996).				

EXAMINER	DATE CONSIDERED
1	,
li .	